CorMedix Completes Acquisition of Melinta Therapeutics, Raises Financial Guidance and Announces New Leadership Team
1. CorMedix acquired Melinta, enhancing its drug portfolio with seven new products. 2. Pro forma revenue guidance for 2025 expected to be $325-$350 million. 3. Transaction will positively affect EPS with double-digit accretion anticipated in 2026. 4. Peak annual sales for REZZAYO™ could exceed $200 million from new indications. 5. DefenCath® may reach peak annual sales of $150-$200 million in TPN indication.